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To estimate the optimal proportion of new patients diagnosed with cancer who require assessment and evaluation for familial cancer
genetic risk, based on the best evidence available. We identified evidence of the patients who require assessment for familial genetic
risk when diagnosed with cancer through extensive literature reviews and searches of guidelines. Epidemiological data on the
distribution of cancer type, presence of a family history, age and other factors that influence referral for genetic assessment were
identified. Decision trees were constructed to merge the evidence-based recommendations with the epidemiological data to
calculate the optimal proportion of patients who should be referred. We identified ‘high probability’ and ‘moderate probability’
groups for having a genetic susceptibility. The proportion of patients diagnosed with cancer in Australia who have a high probability of
having a genetic predisposition and who should be referred for genetic assessment is 1%. If the moderate probability group is also
assessed this proportion increases to 6%. This model has identified the proportion of new patients diagnosed with cancer who should
be referred for genetic assessment. This data is the first step in determining the resources required for provision of an adequate
cancer genetic service.
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Major advances in the understanding of the molecular basis of
cancer have implications for all aspects of cancer management,
including prevention, screening and treatment. Increasing
knowledge about familial cancer syndromes (Lindor et al, 1998),
and the ability to detect specific germline mutations in various
cancer-associated genes (Fearon, 1997) means that cancer genetics
should be included in standard clinical care. Estimates for
which there is a familial predisposition range from 5 to 10%
(Fearon, 1997; Lindor et al, 1998).
Although there are tools available to enable doctors and patients
to estimate cancer risk and prognosis these cannot replace
comprehensive cancer genetics clinics that offer other services to
individuals who are concerned about their family history of cancer.
These services include risk assessment and education, facilitation
of genetic testing, pre- and post-test counselling, provision of
personally tailored cancer risk management options and recom-
mendations, and psychosocial counselling and support services
(Pichert, 2004). The cost effectiveness of genetic testing is
influenced by targeting genetic services to patients with a strong
family history of cancer rather than screening the entire
population (Griffith et al, 2004)
In Australia, the National Health and Medical Research
Council (NHMRC) have published guidelines on the familial
aspects of cancer, recommending that patients with an above-
average risk contributing to the development of their cancer
should be referred to a cancer genetics clinic for further
assessment (NHMRC, 1999a). These ‘at-risk’ individuals are
identified through index relatives who have been diagnosed
with cancer.
The objectives of this study are to estimate the ideal proportion
of new cancer cases that should be referred for genetic assess-
ment from the best available evidence. This will identify the
number of index cases overall and for each tumour type that
requires assessment by a cancer genetics service. The model can
be modified to incorporate new indications for referral as
molecular tests are found or when appropriate prevention
strategies are identified.
MATERIALS AND METHODS
Optimal referral rate
We identified from guidelines the indications for a patient
diagnosed with cancer who requires referral to a cancer genetics
clinic for further assessment, counselling or testing. We also
identified epidemiological evidence for the different attributes
associated with probability of a genetic component of cancer risk.
We used Australian data wherever possible so that the result
would be relevant for local service planning. The model does not
include childhood or rare cancers that account for less than 1% of
all cancer cases.
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In this study, an indication for genetic counselling was defined as a
clinical situation where a hereditary trait is likely to be the primary
cause of the cancer. Identification of this trait would have an effect
on the overall clinical outcome, either for the patient or their
family members. For genetic counselling to be indicated there
must be a diagnostic genetic test available, benefit from screening
or early detection or an appropriate early intervention available to
influence cancer risk and/or survival.
In Australia, the NHMRC have published guidelines on the
familial aspects of cancer, recommending that patients with an
above-average risk contributing to the development of their
cancer should be referred to a cancer genetics clinic for further
assessment (NHMRC, 1999a). Guidance on indications that can be
Table 1 Hierarchy of epidemiological data
Quality of
source Source type
a Australian National Epidemiological data
b Australian State Cancer Registry
g Epidemiological databases from other large international groups
(e.g. SEER)
E Results from reports of a random sample from a population
e Comprehensive multi-institutional database
Z Comprehensive single-institutional database
Y Multi-institutional reports on selected groups (e.g. multi-institutional
clinical trials)
l Single-institutional reports on selected groups of cases
Table 2 Genetics: indications for genetic assessment: levels and sources of evidence
Outcome
no. Clinical scenario indicated
Level of
evidence Reference
Proportion of
patients with
cancer (high)
Proportion of patients
with cancer (high and
moderate)
1 CRC, family history, age one first-degree
relative with CRC age of relativeo50
yearso55 years,
III CCV (2004); NHMRC (1999b) 0.001 0.001
2 CRC, family history, age o55 years, 4one first-
degree relative with CRC age of relative 450
years
III CCV (2004); NHMRC (1999b) o0.001 0.002
3 CRC, family history, o55 years 2 or more first-
degree relatives with CRC
III CCV (2004); NHMRC (1999b) o0.001 o0.001
4 CRC, family history, age 455 years one first-
degree relative with CRC age of relativeo50
years
III CCV (2004); NHMRC (1999b) 0.004 0.004
6 CRC, family history, o55 years 2 or more first-
degree relatives with CRC
III CCV (2004); NHMRC (1999b) 0.001 0.001
7 CRC, no family history of CRC age o55 years,
history of HNPCC related cancer
III CCV (2004); NHMRC (1999b) 0.001 0.001
8 CRC, no family history of CRC age o55 years,
no family history of HNPCC related cancer
III CCV (2004); NHMRC (1999b) o0.001 0.02
9 CRC, no family history of CRC age 455 years,
polyps identified, multiple polyps
III CCV (2004); NHMRC (1999b) 0.001 0.001
12 Breast, female, family history, o50, relative
o40 years
III NCCN (2004) 0.001 0.001
13 Breast, female, family history o50, relative
440 years
III NCCN (2004) o0.001 0.006
14 Breast, female, family history 450, relative
o40 years
III NCCN (2004) 0.002 0.002
16 Breast, female, 4one relative III CCV (2004) 0.001 0.001
17 Breast, female, family history of ovarian cancer III CCV (2004) o0.001 0.004
18 Breast, female, no family history age o50 years III CCV (2004) o0.001 0.018
21 Ovarian cancer, epithelial, family history III NHMRC (1999a); CCV (2004) o0.001 o0.001
22 Ovary, epithelial, one or more relatives with
breast cancer, relative o40 years
III NHMRC (1999a); CCV (2004) o0.001 o0.001
24 Ovary, epithelial, one or more relatives with
colorectal cancer relative o50 years
III NHMRC (1999a); CCV (2004) o0.001 o0.001
33 Endometrium, family history III Smith et al (2002) o0.001 0.001
38 Kidney cancer, adenocarcinoma no family
history, age 450 years multifocal or bilateral
tumours
III o0.001 0.001
40 Kidney cancer, adenocarcinoma family history III CCV (2004) o0.001 o0.001
44 Brain tumour haemangioblastoma III CCV (2004) o0.001 o0.001
46 Soft tissue or bone tumour, age o45years,
family history of cancer, no breast or sarcoma,
relative o45
III CCV (2004) o0.001 0.001
48 Soft tissue or bone tumour, age o45years,
family history of cancer, breast or sarcoma
III CCV (2004) o0.001 o0.001
53 Thyroid cancer, medullary, family history III NCI (2004) o0.001 o0.001
54 Thyroid cancer, medullary, no family history III NCI (2004) o0.001 o0.001
Total proportion of all patients with cancer who should be referred for genetic assessment 0.06 (6%). *Level I, systematic review of all relevant randomised studies; level II, at least
one properly conducted randomised trial; level III, well-designed randomised controlled trials without randomisation. Includes trials with pseudorandomisation or comparative
studies; level IV, case series;
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sTable 3 Genetics: the incidence of attributes used to define indications for referral for genetic assessment
Population of interest Attribute
Proportion of
population with
attribute Reference
Quality of
information
All registry cancers Colorectal cancer 0.14 AIHW (2004) a
Colorectal cancer Family history 0.17 Fuchs et al (1994) g
CRC, family history o55 years 0.38 Fuchs et al (1994) g
0.14 St John et al (1993) l
CRC, family history, o55 years Only one affected relative 0.93 St John et al (1993) l
CRC, family history, o55 years Relative o50 years 0.21 St John et al (1993) l
Only one affected relative
CRC, no family history o55 years 0.17 Kune et al (1989) l
CRC, no family history,o55 Family history of HNPCC related
cancer
0.05 Slattery and Kerber (1994) z
CRC, no family history Proportion of patients with polyps 0.55 Boutron et al (1997) l
455 years,
CRC, no family history Proportion with multiple polyps 0.01 Muto et al (1975) e
455, polyps O’Brien et al (1990)
All registry cancers Breast cancer 0.13 AIHW (2004) a
Breast Cancer Female 0.99 AIHW (2004) a
Breast cancer, female Family history in one 11 or 21 relative 0.22 Slattery and Kerber (1993) z
Family history in 4one 11 relative 0.01
Ovarian cancer in one 11 or 21 relative 0.03
Breast cancer, female Age o50years 0.23 Slattery and Kerber (1993) z
family history of breast cancer
Breast cancer, female Relative o40years 0.15 CGHFBC (2001) y
family history of breast cancer,
age o50years
Breast cancer, female Relative o40years 0.08 CGHFBC (2001) y
family history of breast cancer,
age 450years
Breast cancer, no family history Age o50 years 0.19 Slattery and Kerber (1993) z
All registry cancers Ovarian cancer 0.01 AIHW (2004) a
Ovarian cancer Epithelial 0.9 AIHW (2004) a
Ovarian cancer, epithelial Relative with ovarian cancer 0.03 CGHFBC (2001) e
Relative with breast cancer 0.06 Purdie et al (1995)
Relative with bowel cancer 0.05
Ovarian cancer, epithelial Relative o40 years 0.2 Easton et al (1996) g
Relative with breast cancer
Ovarian cancer, epithelial Relative o50 years 0.13 Easton et al (1996) g
Relative with bowel cancer
All registry cancers Prostate cancer 0.12 AIHW (2004) a
Prostate cancer 43 relatives over 0.07 Bratt et al (1999) e
3 generations Carter et al (1993)
Keetch et al (1995)
All registry cancers Melanoma 0.11 AIHW (2004) a
Melanoma Positive family history 0.1 Aitken et al (1994) b
Ang et al (1998)
All registry cancers Lung cancer 0.1 AIHW (2004) a
All registry cancers Gynaecological cancers 0.04 AIHW (2004) a
excluding ovary
Gynaecological cancers Endometrial cancer 0.56 AIHW (2004) a
excluding ovary
Gynaecological cancers Cervix 0.34 AIHW (2004) a
excluding ovary Vulva 0.07
Vagina 0.03
Endometrial cancer Family history 0.05 Boltenberg et al (1990) y
Gruber and Thompson
(1996); Sandles et al (1992)
All registry cancers Head and neck cancer 0.04 AIHW (2004) a
All registry cancers Lymphoma 0.04 AIHW (2004) a
All registry cancers Unknown primary 0.04 AIHW (2004) a
All registry cancers Kidney cancer 0.03 AIHW (2004) a
Kidney Adenocarcinoma 0.8 AIHW (2004) a
Kidney, adenocarcinoma No family history 0.99 Czene and Hemminki
(2002)
g
Kidney, adenocarcinoma, Multifocal or bilateral cancer 0.05 Neumann et al (1998) e
No family history
All registry cancers Bladder cancer 0.03 AIHW (2004) a
All registry cancers Leukaemia 0.03 AIHW (2004) a
All registry cancers Gastric cancer 0.02 AIHW (2004) a
All registry cancers Pancreatic cancer 0.02 AIHW (2004) a
Pancreatic No family history 0.95 Silverman et al (1999) e
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average) are included.
Four groups were identified:
1. High probability: where the likelihood that a hereditary trait is
the cause of the cancer is substantially greater than average.
This group includes people whose lifetime risk for breast
cancer is likely to be between 25 and 50%, those who meet
the modified Amsterdam criteria for Hereditary non-polyposis
colorectal cancer and those at potentially high risk of
developing ovarian cancer (NHMRC, 1999b).
2. Moderate probability: where the likelihood that a hereditary
trait is the cause of the cancer is greater than average. This
group includes people whose lifetime risk for breast cancer is
likely to be between 12 and 25%, and those who are likely to
have a relative risk of colorectal cancer that is three- to six-fold.
3. Low probability: where the likelihood that a hereditary
trait is the cause of the cancer is no higher than in the general
population.
4. Research: a group where a genetic predisposition may have
contributed to the development of cancer but where currently
no diagnostic genetic test is available, or no benefit from
screening or early detection has been determined or there is no
appropriate early intervention available to influence cancer risk
and/or survival.
Search strategy and selection criteria
We searched the National Guidelines Clearinghouse, Medline and
the major cancer services that have guidelines on the internet for
national level guidelines and guidelines issued by major institu-
tions on the indications for referral to a familial genetics service.
There are Australian NHMRC clinical practice guidelines on
familial aspects of cancer, colorectal cancer, breast cancer and
melanoma. Two American sources of guidelines identified were
the comprehensive Physicians Data Query (PDQ) database of
the US National Comprehensive Cancer Institute (NCI), and the
National Comprehensive Cancer Network (NCCN). The level of
evidence that supported each recommendation for use of genetic
assessment was classified using the Australian NHMRC hierarchy
of levels of evidence.
The optimal genetic assessment utilisation tree was constructed
using TREEAGE DATAt software (version 3.5). Each terminal
branch represents either ‘referral for genetic assessment’ or ‘no
referral for genetic assessment’ as the management decision. The
proportion of patients requiring referral for genetic assessment
was subdivided into patients who should be categorised as having
either a high or moderate probability of hereditary cancer.
Each branch of the tree signifies an attribute that affects a
management decision (e.g. other family member with cancer).
Above each branch is a description of the specific attribute that has
led to that decision. Each number below the branch signifies the
proportions of the attribute based on epidemiological data.
Epidemiological data
The source with the highest ranking was used to determine the
incidence of each indication for genetic assessment. We used
Australian national and state cancer registry epidemiological data
wherever available to make the results of this study relevant for
planning future cancer genetic services in Australia. When national
data were unavailable, more specific data sets were used according
to a published hierarchy. Epidemiological data were ranked
according to the schema in Table 1.
RESULTS
The clinical situations for which referral for genetic assessment is
recommended, and the guideline or source of evidence for the
recommendation are tabulated (Tables 2 and 3). In Table 2, the
outcome numbers correspond to the outcome positions in the tree
(Figure 1A and B). The last column represents the incidence of
each clinical indication for referral for genetic assessment
as a proportion of patients diagnosed with cancer. Table 3 show
the epidemiological data corresponding to each branch point,
Table 3 (Continued)
Population of interest Attribute
Proportion of
population with
attribute Reference
Quality of
information
All registry cancers Brain tumour 0.02 AIHW (2004) a
Brain tumour Haemangioblastoma 0.02 l
All registry cancers Soft tissue and bone 0.01 AIHW (2004) a
Soft tissue and bone o45 years 0.3 AIHW (2004) a
Soft tissue and bone, Family history of cancer 0.05
o45 years
Soft tissue and bone Family history of breast or sarcoma 0.28 Moutou et al (1996) l
o45 years, family history
of cancer
Soft tissue and bone Cancer in relative o45 years 0.17 Moutou et al (1996) l
o45 years,no family history
of cancer
All registry cancers Thyroid 0.01 AIHW (2004) a
Thyroid cancer Papillary 0.72 Hundahl et al (1998) g
Follicular 0.21
Medullary 0.05
Anaplastic 0.02
Medullary thyroid cancer Familiy history 0.26 Moley et al (1998) l
All registry cancers Liver cancer 0.01 AIHW (2004) a
All registry cancers Oesophagus 0.01 AIHW (2004) a
All registry cancers Gallbladder cancer 0.01 AIHW (2004) a
All registry cancers Myeloma 0.01 AIHW (2004) a
All registry cancers Testicular cancer 0.01 AIHW (2004) a
All registry cancers Other 0.01 AIHW (2004) a
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sand the source of the data, as well as the hierarchical level of the
data, obtained.
Each branch of the tree (Figure 1A and B) signifies an attribute
that affects a management decision. Above each branch is a
description of the specific attribute that has led to the treatment
decision. Each number below the branch signifies the propor-
tions of the attribute based on epidemiological data. Each
terminal branch of the tree showed whether or not referral for
genetic assessment was recommended for patients with those
particular attributes.
Outcome
There were possible 68 ‘outcomes’ for this tree of which 16
recommended that patients had a high probability of familial
cancer and should be considered for referral to a cancer
genetics service. A further nine ‘outcomes’ classified patients as
at least moderate risk. The optimal proportion of patients
diagnosed with cancer who should be referred for genetic
assessment for high or moderate risk was calculated to be
0.06, that is, 6% of all patients diagnosed with cancer in
Proband age at diagnosis
One first-degree relative
One or more first-degree relatives
One first-degree relative
with CRC
with CRC
Two or more first-degree relatives
Relative's age at diagnosis
<50 years (high risk)
Relative's age at diagnosis
<50 years (high risk)
Relative's age at diagnosis
>50 years
Relative's age at diagnosis
Relative's age at diagnosis <40 years
Relative's age at diagnosis >40 years
Relative's age at diagnosis >40 years
Relative's age at diagnosis >40 years
>50 years
with CRC
Two or more first-degree relatives
with CRC
Proband age at diagnosis
Proband age at diagnosis
Proband age at
Proband age at
Proband age at
Proband age at
Proband age at diagnosis
Family history of
No family history of
No family history of HNPCC
Family history of BC in one
Family history of HNPCC
related cancer (high)
related cancer
Polyps identified at time
No polyps identified at time
of diagnosis with CRC
of diagnosis with CRC
No family history of breast cancer
or relative more distant than second degree
Female
Male
Cancer
Breast (BC)
Family history of BC in greater than one
first or second-degree relative
First or second-degree relative
with ovarian cancer
with breast cancer
One or more first-degree relatives
with ovarian cancer
One or more first-degree relatives
Family history of other cancer
with colorectal cancer
or no cancer
Ovary
Non-epithelial
Epithelial
Low
Low
Low
Low
Low
Low
Low
Low
Medium
Medium
Medium
Medium
Medium
first degree relative (high)
CRC
CRC
Colorectal (CRC)
0.14
0.93
0.2
0.8
0.2
0.8
0.93
0.07
0.07
0.05
0.95
0.99
0.15
0.85
0.92
0.08
0.01
Multiple colonic polyps
Few colonic polyps 0.55
0.45
0.86
0.83
0.22
0.99
0.13
0.03
0.19
0.19
0.81
0.81
0.2
0.8
0.13
0.87
High
Relative diagnosed <40 years
Relative diagnosed >40 years
Relative diagnosed <50 years
Relative diagnosed >50 years
High
High
High
High
High
High
High
High
High
High
Low
Low
High
0.74
0.03
0.06
0.07
0.84
0.01
0.01
0.01
0.9
0.17
0.17
0.14
0.83
<55 years (moderate risk)
<55 years (moderate risk)
diagnosis<50 years (moderate)
diagnosis<50 years (moderate)
diagnosis >50 years
diagnosis>50 years
>55 years
>55 years
A
Figure 1 (A) Optimal referral for genetic assessment tree for colorectal, breast and ovarian cancer. (B) Optimal referral for genetic assessment tree for
other cancers.
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sAustralia should be referred for genetic assessment, based upon
the best available evidence. The optimal proportion of ‘high-
probability’ patients is 1%.
Referral for cancer genetic assessment has the greatest impact
for patients diagnosed with breast, colorectal and ovarian cancer.
The proportion of patients diagnosed with each of these cancers
who are at moderate or high probability are shown in Table 4 and
Figure 1A.
Prostate cancer and melanoma fall into the group that is of
research interest at present. The proportions of patients for whom
genetic assessment may be eventually indicated were 7 and 1%,
respectively.
Family members
No family member
No family history
Endometrium
Melanoma
Gynaecological cancer
excluding ovary
Family history
Prostate
0.12
0.1
0.11
0.9
Family history
Family history
Family history of
Family history of cancer
in a relative
No family history of 
cancer in a relative
No family history
No family history
Cancer in relative
Cancer in relative
<45 years
>45 years
of breast or sarcoma
breast or sarcoma
No family history
Multifocal or
Not multifocal or
bilateral
0.95
0.05
bilateral renal cancer
0.56
0.34
0.04
0.07
0.03
0.01
0.99
0.28 0.27
0.01
Papillary
Follicular
Medullary
Anaplastic
Soft tissue or bone tumour
Thyroid Cancer
0.01
0.73
0.72
0.21
0.02
0.05
0.74
0.26
0.72
0.05
0.95
0.17
0.8
0.2
0.02
0.05
0.95
0.98
Age>45 years
Age<45 years
0.02
0.02
0.03
Kidney
Other cancers
that have indications for
genetic testing
Adenocarcinoma
All other brain tumours
Papillary
Family history
Family history
No family history
No family history
Haemangioblastoma
Pancreas
Brain
Cervix
Vulva
Vagina
0.93
0.06
0.94
0.95
0.05
Research
Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
High
Low
Low
High
High
Low
Low
Low
Low
Medium
High
Medium
Medium
Medium
Research
Low
3 or more
first-degree relatives
<3 first-degree relatives
0.07
(>3 relatives over 3 generations)
0.83
B
Figure 1 Continued
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All oncology providers must be aware of the hallmarks of
susceptibility to hereditary cancer in order to appropriately
identify patients who might benefit from comprehensive cancer
genetic counselling. Guidelines on patients who are at risk have
been published by national groups (Trepanier et al, 2004) to help
identify patients who require referral. Variations in referral may
result from both lack of proper identification of an ‘at risk’
individual, clinician’s nihilism in what can be achieved by
screening or earlier diagnosis or variations in accessibility to
these clinics (McDonald et al, 2004).
Both International and National guidelines and data were used
to complete this study, and it is therefore thought to be broadly
applicable. Australian cancer registry data were used for the initial
proportions of each cancer type. This is recorded in the first
column of Table 4. The model can be adapted for regional services
planning by incorporating data from national or local cancer
registries. This study not only identifies the overall proportion of
patients who might benefit from referral, but also the proportion
by each cancer type. These models can be used to identify who
should be considered for referral, dependent on patients’ wishes
and relatives who might benefit from the information obtained.
This model identifies the probability for newly diagnosed cancer
patients for whom an inherited trait might be identified, and early
intervention or screening may be warranted. The model does not
include childhood or rare cancers such as phaeochromocytoma,
although there is emerging evidence of a genetic predisposition
(Neumann et al, 2002), or retinoblastoma, where all new cases
should be referred for genetic assessment.
Currently in Australia only patients who are at high risk are
eligible for referral. However, an optimal service should include
referral of patients who are at high and moderate probability of
having a genetic susceptibility, where confirmation of the family
history and more detailed assessment of their probability of
genetic predisposition can be determined by genetic counsellors
and specialists.
Comprehensive reviews of both the psychological impact and an
economic evaluation of testing and counselling have been
performed (Braithwaite et al, 2004; Griffith et al, 2004). Genetic
counselling for familial cancer is associated with an improvement
in knowledge but does not have an adverse effect on affective
outcomes.
This model identifies the optimal number requiring counselling
if all index cases have a single relative who wishes to benefit
from this service. It starts with the index case rather than the
unaffected person concerned about their family history. For
each index case data on family members is required with the
number requiring referral ranging from no family members
to several. This data is not currently available but may be
obtainable from local databases for some of the commoner
malignancies.
From the optimal proportion identified in this study, further
work is required to determine the actual number of patients
diagnosed with cancer in each tumour site that require access to
this service, and the number of relatives that may require
assessment when a genetic predisposition is identified. This can
be included in the economic evaluation to help determine the value
of this service to individuals, families and society. Work is also
required to assess why patients may not be referred to a cancer
genetic service, which is likely to include lack of awareness
of the benefits of counselling and testing, lack of access to a
service, patient refusal, no relatives or no family members residing
in the country, and referring doctors’ uncertainty as to the
benefits of the service.
CONCLUSIONS
The planning of efficient cancer genetics services for a popula-
tion requires a rationale estimate of its need. This model iden-
tifies the proportion of patients with cancer who may benefit
from such a service by using an evidence-based approach and is
the first step to appropriate planning and resourcing of cancer
genetics services. Further research is required to identify both
the actual proportion of the population who are referred to a
cancer genetics service and also reasons why patients are currently
not referred.
Table 4 Proportion of patients who require assessment by tumour site and probability
Tumour type
Proportion of new
cancers in Australia
Role for
genetics High %
High and
moderate % Moderate % Low % Research %
Colorectal 14 Yes 5 21 16 79
Breast 13 Yes 3 24 21 76
Ovary 1 Yes 5 5 0 95
Gynae-ovary 4 Yes 0 3 3 97
Kidney 3 Yes 0 5 5 95
Brain 2 Yes 2 2 0 100
Sarcoma 1 Yes 1 1 0 99
Thyroid 1 Yes 1 5 4 95
Lung 10 No 0 0 0 100
Prostate 12 Yes 0 0 7 93 7
Melanoma 11 Yes 0 0 1 99 1
Head and neck 4 No 0 0 0 100
Lymphoma 4 No 0 0 0 100
UK primary 4 No 0 0 0 100
Bladder 3 No 0 0 0 100
Leukaemia 3 No 0 0 0 100
Gastric 2 No 0 0 0 100
Pancreas 2 No 0 0 0 100
Liver 1 No 0 0 0 100
Oesophagus 1 No 0 0 0 100
Gallbladder 1 No 0 0 0 100
Myeloma 1 No 0 0 0 100
Testes 1 No 0 0 0 100
Other 1 No 0 0 0 100
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